文献速递头颈与中枢神经肿瘤

循环游离DNA中的5-羟甲基胞嘧啶作为鼻咽癌诊断生物标志物

5-Hydroxymethylcytosines in circulating cell-free DNA as a diagnostic biomarker for nasopharyngeal carcinoma.
PubMed 文献 · Eur J Cancer · 2024-09-07

研究分析174例鼻咽癌患者和146例非癌个体的游离DNA 5hmC图谱,构建12基因5hmC诊断模型。模型区分鼻咽癌与非癌样本的AUC在训练集为0.97、测试集为0.93,优于EBV DNA检测,对早期及EBV阴性鼻咽癌也有较高诊断能力。

要点

  • 基于cfDNA 5hmC的12基因诊断模型可有效区分鼻咽癌与非癌样本。
  • 模型对早期鼻咽癌和EBV阴性鼻咽癌均表现出较高的诊断AUC。
  • 该模型诊断性能优于EBV DNA检测,为有前景的无创生物标志物。

核心结论

  • cfDNA中的5hmC修饰是有前景的鼻咽癌无创生物标志物,具有高灵敏度和特异度,尤其适用于早期和EBV阴性鼻咽癌。

研究设计与样本

  • 研究纳入174例鼻咽癌患者和146例非癌个体,采用5hmC-Seal技术分析cfDNA全基因组5hmC图谱。
  • 使用LASSO逻辑回归构建基于cfDNA 5hmC的诊断模型,并通过ROC曲线和混淆矩阵评估性能。

主要发现

  • 鼻咽癌患者的5hmC-Seal数据全基因组分布与非肿瘤样本不同。
  • 12基因5hmC标志物组合区分鼻咽癌与非癌样本的AUC在训练集为0.97(95%CI:0.94-0.99),测试集为0.93(95%CI:0.88-0.98),优于EBV DNA检测。
  • 诊断评分区分非癌个体与早期鼻咽癌的AUC在训练集为0.99(95%CI:0.98-1),测试集为0.98(95%CI:0.95-1)。
  • 诊断评分区分非癌个体与晚期鼻咽癌的AUC在训练集为0.96(95%CI:0.93-0.99),测试集为0.93(95%CI:0.88-0.98)。
  • 在EBV阴性患者中,诊断评分区分EBV阴性鼻咽癌与非癌个体的AUC在训练集为0.94(95%CI:0.88-1),测试集为0.91(95%CI:0.81-1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the diagnostic value of 5-hydroxymethylcytosines (5hmC) in circulating cell-free DNA (cfDNA) for nasopharyngeal carcinoma (NPC) and to develop a diagnostic model. METHODS: Genome-wide 5hmC profiles in cfDNA from 174 NPC patients and 146 non-cancer individuals were analyzed using the 5hmC-Seal technique. A cfDNA 5hmC-based diagnostic model to identify NPC patients was developed using least absolute shrinkage and selection operator (LASSO) logistic regression, and performance was evaluated with receiver operating characteristic (ROC) curves and confusion matrices. RESULTS: The 5hmC-Seal data from patients with NPC showed a different genome-wide distribution than non-tumor samples. Our initial analysis revealed a 12-gene-based 5hmC marker panel to be an accurate diagnostic model effectively distinguishing between NPC samples and non-cancerous samples (training set: area under curve (AUC)= 0.97 [95 % CI: 0.94-0.99]; and test set: AUC= 0.93 [95 % CI: 0.88-0.98]) superior to EBV DNA testing. The diagnostic score performed well in differentiating the non-cancer subjects from early-stage NPC (training set: AUC=0.99 [95 % CI: 0.98-1]; test set: AUC=0.98 [95 % CI: 0.95-1]), and advanced-stage NPC (training set: AUC=0.96 [95 % CI: 0.93-0.99]; test set: AUC=0.93 [95 % CI: 0.88-0.98]). Notably, in EBV-negative patients, the diagnostic scores showed excellent capacity for distinguishing EBV-negative patients with NPC from non-cancer subjects in both the training set (AUC= 0.94 [95 % CI: 0.88-1]) and test set (AUC=0.91 [95 % CI: 0.81-1]). CONCLUSION: 5hmC modifications in cfDNA are promising noninvasive biomarkers for NPC, offering high sensitivity and specificity, particularly for early-stage and EBV-negative NPC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Chen B, Wang D, Xu Y, et al. 5-Hydroxymethylcytosines in circulating cell-free DNA as a diagnostic biomarker for nasopharyngeal carcinoma. Eur J Cancer. 2024. PMID: 39213787. doi:10.1016/j.ejca.2024.114294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。